Precigen Inc
PGENHealthcare|Biotechnology|USA
$5.33
-0.21 (-3.80%)
Tangible Book
$0.01
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06538480 Zopa Retreatment and Vector Shedding in Adults With RRP | Recurrent Respiratory Papillomatosis, Papillomavirus Infection | P4 | Recruiting | 30 | Open-label | Zopapogene imadenovec (Zopa) |
| NCT04724980 Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | Recurrent Respiratory Papillomatosis, Papillomavirus Infections | P1P2 | Active | 38 | Open-label | PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2 |
| NCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Cervical Cancer, HPV-Related Carcinoma | P2 | Recruiting | 24 | Open-label | PRGN-2009 plus Pembrolizumab |
| NCT03927261 PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P1 | Active | 88 | Open-label | PRGN-3006 T Cells |
| NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | P1 | Active | 71 | Open-label | PRGN-3005 UltraCAR-T cells, PRGN-3005 UltraCAR-T cells |
| NCT03751007 A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) | Diabetes type1 | P1P2 | Completed | 45 | RCT, Double-blind | AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose, AG019 - High Dose |
| NCT05694364 Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P1 | Completed | 3 | Open-label | Fludarabine, Cyclophosphamide, PRGN-3007 |
| NCT03409627 Novel INXN-4001 Triple Effector Plasmid in Heart Failure | Heart Failure, Cardiovascular Diseases | P1 | Completed | 12 | Open-label | INXN-4001 |